SCHEMBL10175634

SCHEMBL10175634

COC(=O)[C@@H](OC(C)(C)C)c1c(C)nc2cc(-c3ccc4c(c3)CCCC4)nn2c1-c1ccc2c(c1)CCCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 1/20 0.51
▸ PSIP1 O75475 1/20 0.38
▸ ALDH1A1 P00352 5/20 0.35
▸ LMNA P02545 4/20 0.35
▸ MAPT P10636 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ HTT P42858 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ P2RX3 P56373 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459320 0.92 NR1I2 (0.60) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL458952 0.92 NR1I2 (0.60) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL10175499 0.89 NR1I2 (0.48) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL470438 0.89 NR1I2 (0.63) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL470378 0.88 NR1I2 (0.50) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL470382 0.88 NR1I2 (0.47) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL12091046 0.86 NR1I2 (0.68) NR1I2PSIP1ALDH1A1LMNASMN1; SMN2
SCHEMBL10175404 0.86 NR1I2 (0.61) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL10175637 0.86 CYP3A4 (0.51) NR1I2PSIP1ALDH1A1LMNAMAPT
SCHEMBL461172 0.85 NR1I2 (0.74) NR1I2PSIP1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 — — US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 — — US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 — — US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 — — US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885PSIP1 1676/4885ALDH1A1 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback